Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.
Salience Labs is building a hybrid photonic-electronic chip for AI. The company in photonic solutions aimed at enhancing connectivity for AI data center infrastructure. The company emerged from over a decade of research at the University of Oxford and the University of Münster, focusing on silicon photonics to address the growing demands of AI workloads. The company's flagship product is an optical switch designed to facilitate all-optical networking between compute nodes. This innovation aims to eliminate bottlenecks in data movement, offering low-latency, high-bandwidth networking that accelerates job completion while reducing power consumption and costs.
Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, and bioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal.
Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models.
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.
PetMedix is a development stage veterinary biopharmaceutical company based in Cambridge, UK. they are using the highest quality science to make the therapies their pets need and deserve, keeping them healthier, happier, and for longer. Building on more than thirty years of world-leading innovation and human drug development, they are applying the cutting edge of science to bring breakthroughs for the animals they love and care for.
CMR Surgical develops a surgical robotic system for minimal access surgery. It makes minimal-access surgery universally accessible and affordable by significantly expanding the range of procedures that robots can perform and allowing surgeons to access 3D high-definition imagery and feedback during the operation.
Origami is on a mission to build a green energy world, powered by smart technology. As renewables grow, energy markets are becoming more complex and volatile. Origami's intelligent trading and automation software enables energy companies to continuously harness the shifting commercial opportunities of the global energy transition and optimise increasingly complex physical, financial, and contractual positions. Origami's real-time data platform provides a modular suite of solutions incorporating state-of-the-art machine learning technology, all designed to deliver more efficient, resilient, and profitable trading operations across the entire power production, planning and energy trading workflow.
Sense Biodetection Limited is a molecular diagnostics company focused on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology.
Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.
Riverlane creates and engineers instruments. With the help of the manufacturers of quantum computers, they put them into practice. New hardware and software tools are needed to regulate intrinsically unstable qubits and completely fix system defects ten billion times or more per second in order to unlock the entire range of quantum computing applications.
Secondmind is on a mission to help automotive innovators design cleaner cars, and achieve greater sustainability through machine learning. Underpinned by years of award-winning, practical machine learning research and technology, developed by a world-class team of researchers, data scientists and machine learning engineers, Secondmind is helping Automotive manufacturers navigate the increasing complexity of engineering design in its transition to electrification. Secondmind was founded in 2016 and is backed by leading venture funds including Amadeus Capital, Atlantic Bridge, and Cambridge Innovation Capital, among others.
Seldon enables ml engineering teams to accelerate from r and d to production with proven efficiency gains. Its customers include large enterprises across sectors and geographies, including leaders in technology, pharma, automotive, finance, and retail. Their open-source projects are considered in model serving, explanations, and monitoring with installs and models deployed.
Congenica is a biotechnology company that provides a diagnostic decision support platform. They have translated this research into the gold standard clinical genomic analytics platform, Sapientia, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians to provide an actionable interpretation of genetic disease for patients. It was founded in 2013 and headquartered in Cambridge, Cambridgeshire.
GeoSpock enables data fusion for the connected world with GeoSpock DB – the space-time analytics database. GeoSpock DB is a unique, cloud-native database optimised for querying for real-world use cases, able to fuse multiple sources of Internet of Things (IoT) data together to unlock its full value, whilst simultaneously reducing complexity and cost. GeoSpock DB enables efficient storage, data fusion, and rapid programmatic access to data, and allows you to run ANSI SQL queries and connect to standard analytics tools via flexible JDBC/ODBC connectors. Users are able to perform deep analysis and share insights using familiar toolsets, with plug and play support for common BI tools (such as Tableau™, Amazon QuickSight™, and Microsoft Power BI™), and Data Science and Machine Learning environments (including Python Notebooks and Apache Spark). The database can also be integrated with proprietary applications, web services, and internal tools – with compatibility for open-source and customisable visualisation libraries such as Kepler and Cesium.js.
Audiotelligence leads the world in blind audio signal separation from multi-microphone captured audio. Our AudioTelligence nD technologies greatly out-perform existing 'state-of-the art' commercially available technologies such as beam forming, spectral masking, deep neural nets, non-negative matrix factorisation and ICA.
Sense Biodetection Limited is a molecular diagnostics company focused on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology.
CMR Surgical develops a surgical robotic system for minimal access surgery. It makes minimal-access surgery universally accessible and affordable by significantly expanding the range of procedures that robots can perform and allowing surgeons to access 3D high-definition imagery and feedback during the operation.
Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.
PredictImmune is developing pioneering tools for guiding treatment options in immune-mediated inflammatory diseases with the first product addressing Inflammatory Bowel Disease (both Crohn’s and ulcerative colitis). Based on world-leading research at Cambridge University, UK, they are developing a simple lab test, using a small blood sample, which accurately identifies patients at diagnosis who are at risk of experiencing severe, relapsing disease. These patients are likely to benefit from early biologics therapy. Physicians, patients and payors all recognise the value of such an approach to the management of Inflammatory Bowel Disease.
Riverlane creates and engineers instruments. With the help of the manufacturers of quantum computers, they put them into practice. New hardware and software tools are needed to regulate intrinsically unstable qubits and completely fix system defects ten billion times or more per second in order to unlock the entire range of quantum computing applications.
At Audio Analytic, we create exceptional human experiences through a greater sense of hearing. We do this by partnering with leading consumer tech companies to bring intelligence and context to their products through an accurate, robust and compact sense of hearing. This ‘greater sense of hearing’ will help us remember the past, help, improve and extend our hearing in the present and anticipate what we need in the very near future. Our embedded software platforms (ai3™ and ai3-nano™) have been licensed to some of the world’s most prominent companies and are suitable for a wide range of products from smart speakers and video doorbells to smartphones, xR glasses and true wireless earbuds.
Secondmind is on a mission to help automotive innovators design cleaner cars, and achieve greater sustainability through machine learning. Underpinned by years of award-winning, practical machine learning research and technology, developed by a world-class team of researchers, data scientists and machine learning engineers, Secondmind is helping Automotive manufacturers navigate the increasing complexity of engineering design in its transition to electrification. Secondmind was founded in 2016 and is backed by leading venture funds including Amadeus Capital, Atlantic Bridge, and Cambridge Innovation Capital, among others.
Targeting pathways that modify RNA to deliver novel cancer therapeutics.
PolyProx Therapeutics is developer of a novel class of drug intended to provide new therapies for cancer treatment. The company's drug will use novel engineered protein that is able to selectively target tumour cells and trigger natural degradation machinery within the cell, enabling cancer patients to benefit from the treatment that targets and remove disease-causing proteins.
Cytora is a configurable platform that enables commercial insurers to process risks at greater efficiency and accuracy. Cytora digitises every incoming risk, augments them with additional data sources, evaluates them against multiple rules, including appetite and priority rules, and routes them to downstream systems for automated or manual underwriting. Cytora was founded in 2014 and is headquartered in London.
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated.
Pragmatic is a ultra-low-cost flexible electronics. Their flexible integrated circuits (FlexICs) are thinner than human hair and can be invisibly embedded in objects, enabling innovators to create novel solutions to everyday problems that are not practical with conventional electronics. Designers can create their own application-specific flexible devices using our FlexIC Foundry® service at a fraction of the cost and time required for traditional silicon circuits, opening up multiple new markets. We also offer standard FlexIC products that extend proven applications such as RFID and NFC into mass market use cases, enabling the potential for trillions of smart objects that can engage with consumers and their environments. All FlexICs are manufactured on our revolutionary FlexLogIC® production system, a highly scalable manufacturing model for cost-effective high-volume production, achieved with orders of magnitude lower capital investment and operating cost compared to a traditional silicon IC fab. Our novel, differentiated technology is being adopted by a growing base of global companies across diverse markets, including consumer goods, retail, healthcare, pharmaceutical, gaming and security. Pragmatic is headquartered in Cambridge, UK, with our first billion-unit production facility in Sedgefield. Shareholders include Cambridge Innovation Capital, Arm and Avery Dennison.
Imagen is a modular enterprise video platform that enables content owners to publish and monetize small and large-scale media archives. It helps companies of all sizes and industries to manage, search and distribute their media libraries securely.
MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins as a novel therapy for the treatment for pulmonary arterial hypertension Pulmonary arterial hypertension is a severe and life-limiting disease that affects the blood vessels in the lungs, leading to heart failure, and leaves sufferers feeling breathless and exhausted. Current treatments mainly target symptoms and the prognosis remains poor. The only effective cure is transplantation of the lungs or heart and lungs, which has associated risks and complications. Compromised bone morphogenetic protein (BMP) receptor type II (BMPR-II) signalling in endothelial cells plays a pivotal role in the pathobiology PAH, as identified from human genetic studies. BMP9 and 10 represent circulating ligands that selectively bind and activate BMPR-II receptor complexes on endothelial cells. Administration of exogenous BMP9 has been shown to augment endothelial BMPR-II signalling and reverse PAH in several rodent models of disease. Our goal is to explore the potential of BMP9 and BMP10 as potential therapies for PAH. The company follows the semi-virtual model with a hub based in Cambridge, UK. The company founders are experts in the field of PAH and BMPs. The team is staffed with experienced drug discovery professionals to direct an out-sourced development program. This model ensures maximum capital efficiency without sacrificing quality.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
CEDAR Audio is the world's only company dedicated solely to audio restoration and speech enhancement for film, post, TV and radio broadcast, CD and DVD mastering, libraries and archives, and for audio forensic investigation. Established in 1988 following five years of research funded by the British Library National Sound Archive, CEDAR Audio is based in Cambridge, UK, and retains strong academic links with Cambridge University, itself one of the world's leading centres for digital signal processing research. The company currently numbers two Cambridge University Professors and a Director of Studies among its Directors, further strengthening its ability to remain at the forefront of its field. CEDAR Audio is committed to furthering the science and technology of audio restoration and speech enhancements in all its forms. It not only manufactures many of the leading products in these fields, but actively pursues research into new techniques in each of them. The company also places a premium on the highest standards of customer support, and has earned numerous accolades in this area.
Audiotelligence leads the world in blind audio signal separation from multi-microphone captured audio. Our AudioTelligence nD technologies greatly out-perform existing 'state-of-the art' commercially available technologies such as beam forming, spectral masking, deep neural nets, non-negative matrix factorisation and ICA.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Swim.Ai, Inc. develops advance analytics software that processes data in devices at the edge of a network. The company’s product includes SWIM EDX turns all streaming edge data into insights and predictions in real-time without the challenges of big data. It offers solutions for original equipment manufacturers, service providers, enterprises, cities, Internet of Things (IoT) vendors, and developers. It combines edge computing, machine learning, and self-training digital twins in mesh architecture. The company was founded in 2015 and is based in San Jose, California.
Undo is the time travel debugging company for Linux. We equip developers with the technology to understand complex code and fix bugs faster. Developers spend far too much time figuring out what code actually does – either to find and fix bugs or to understand other people’s code. With time travel debugging, developers can see exactly what the software did, and create better software faster. By integrating Undo’s LiveRecorder into their CI workflow, C/C++, Go, and Java software teams can easily and quickly diagnose the root causes of new regressions, legacy bugs, and flaky tests – before they hit customers. Thousands of developers across leading technology firms including SAP, Juniper Networks, and Siemens use LiveRecorder to improve developer productivity, developer velocity, and software quality.
CMR Surgical develops a surgical robotic system for minimal access surgery. It makes minimal-access surgery universally accessible and affordable by significantly expanding the range of procedures that robots can perform and allowing surgeons to access 3D high-definition imagery and feedback during the operation.
Origami is on a mission to build a green energy world, powered by smart technology. As renewables grow, energy markets are becoming more complex and volatile. Origami's intelligent trading and automation software enables energy companies to continuously harness the shifting commercial opportunities of the global energy transition and optimise increasingly complex physical, financial, and contractual positions. Origami's real-time data platform provides a modular suite of solutions incorporating state-of-the-art machine learning technology, all designed to deliver more efficient, resilient, and profitable trading operations across the entire power production, planning and energy trading workflow.
GeoSpock enables data fusion for the connected world with GeoSpock DB – the space-time analytics database. GeoSpock DB is a unique, cloud-native database optimised for querying for real-world use cases, able to fuse multiple sources of Internet of Things (IoT) data together to unlock its full value, whilst simultaneously reducing complexity and cost. GeoSpock DB enables efficient storage, data fusion, and rapid programmatic access to data, and allows you to run ANSI SQL queries and connect to standard analytics tools via flexible JDBC/ODBC connectors. Users are able to perform deep analysis and share insights using familiar toolsets, with plug and play support for common BI tools (such as Tableau™, Amazon QuickSight™, and Microsoft Power BI™), and Data Science and Machine Learning environments (including Python Notebooks and Apache Spark). The database can also be integrated with proprietary applications, web services, and internal tools – with compatibility for open-source and customisable visualisation libraries such as Kepler and Cesium.js.
Cytora is a configurable platform that enables commercial insurers to process risks at greater efficiency and accuracy. Cytora digitises every incoming risk, augments them with additional data sources, evaluates them against multiple rules, including appetite and priority rules, and routes them to downstream systems for automated or manual underwriting. Cytora was founded in 2014 and is headquartered in London.
CMR Surgical develops a surgical robotic system for minimal access surgery. It makes minimal-access surgery universally accessible and affordable by significantly expanding the range of procedures that robots can perform and allowing surgeons to access 3D high-definition imagery and feedback during the operation.
Secondmind is on a mission to help automotive innovators design cleaner cars, and achieve greater sustainability through machine learning. Underpinned by years of award-winning, practical machine learning research and technology, developed by a world-class team of researchers, data scientists and machine learning engineers, Secondmind is helping Automotive manufacturers navigate the increasing complexity of engineering design in its transition to electrification. Secondmind was founded in 2016 and is backed by leading venture funds including Amadeus Capital, Atlantic Bridge, and Cambridge Innovation Capital, among others.
Z Factor Limited is a drug discovery company founded in 2015 to identify and develop therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was created by Index Ventures in partnership with the University of Cambridge.
Congenica is a biotechnology company that provides a diagnostic decision support platform. They have translated this research into the gold standard clinical genomic analytics platform, Sapientia, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians to provide an actionable interpretation of genetic disease for patients. It was founded in 2013 and headquartered in Cambridge, Cambridgeshire.
At Audio Analytic, we create exceptional human experiences through a greater sense of hearing. We do this by partnering with leading consumer tech companies to bring intelligence and context to their products through an accurate, robust and compact sense of hearing. This ‘greater sense of hearing’ will help us remember the past, help, improve and extend our hearing in the present and anticipate what we need in the very near future. Our embedded software platforms (ai3™ and ai3-nano™) have been licensed to some of the world’s most prominent companies and are suitable for a wide range of products from smart speakers and video doorbells to smartphones, xR glasses and true wireless earbuds.
Exvastat is an innovative, preclinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The new treatment has the potential to significantly reduce the high mortality and incapacitating morbidities caused by ARDS, as well as the costs of caring for these critically ill patients to health service providers.
Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models.
Imagen is a modular enterprise video platform that enables content owners to publish and monetize small and large-scale media archives. It helps companies of all sizes and industries to manage, search and distribute their media libraries securely.
Undo is the time travel debugging company for Linux. We equip developers with the technology to understand complex code and fix bugs faster. Developers spend far too much time figuring out what code actually does – either to find and fix bugs or to understand other people’s code. With time travel debugging, developers can see exactly what the software did, and create better software faster. By integrating Undo’s LiveRecorder into their CI workflow, C/C++, Go, and Java software teams can easily and quickly diagnose the root causes of new regressions, legacy bugs, and flaky tests – before they hit customers. Thousands of developers across leading technology firms including SAP, Juniper Networks, and Siemens use LiveRecorder to improve developer productivity, developer velocity, and software quality.
Pragmatic is a ultra-low-cost flexible electronics. Their flexible integrated circuits (FlexICs) are thinner than human hair and can be invisibly embedded in objects, enabling innovators to create novel solutions to everyday problems that are not practical with conventional electronics. Designers can create their own application-specific flexible devices using our FlexIC Foundry® service at a fraction of the cost and time required for traditional silicon circuits, opening up multiple new markets. We also offer standard FlexIC products that extend proven applications such as RFID and NFC into mass market use cases, enabling the potential for trillions of smart objects that can engage with consumers and their environments. All FlexICs are manufactured on our revolutionary FlexLogIC® production system, a highly scalable manufacturing model for cost-effective high-volume production, achieved with orders of magnitude lower capital investment and operating cost compared to a traditional silicon IC fab. Our novel, differentiated technology is being adopted by a growing base of global companies across diverse markets, including consumer goods, retail, healthcare, pharmaceutical, gaming and security. Pragmatic is headquartered in Cambridge, UK, with our first billion-unit production facility in Sedgefield. Shareholders include Cambridge Innovation Capital, Arm and Avery Dennison.
Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated. The company's therapeutics target molecular pathways that drive the most aggressive and resistant forms of cancer using innovative mechanisms, enabling cancer patients to get their predictive biomarkers detected and get their treatments started from early stage.
PervasID is developing a high reliability, wide area passive RFID system with the potential to provide location capability based on the EPC Class1 Gen2 standard. Spun out from research activity in the Engineering Department at the University of Cambridge, the technology is now successfully deployed in several field trials.
Fluidic Analytics was formed in 2013 as a spin-out from the Department of Chemistry at the University of Cambridge. Their roots stretch back to a group of scientists who were inspired by the roles that proteins play in the biological world, driven to understand more about how proteins behave and function, but frustrated by the lack of suitable tools for protein characterisation. So they decided to invent their own. Their vision is that protein science will transform their understanding of how the biological world operates in real time. They believe that this transformation will be every bit as revolutionary as the way that advances in DNA sequencing have transformed their understanding of how the biological world operates over decades, lifetimes and generations. And they believe that Fluidic Analytics can help make this vision a reality by developing products that enable easier, faster, more convenient and more accurate protein characterisation, whether in the lab, at the bedside or in everyday life. They've combined cutting edge technology, a fantastic team and best practice in management and communication to go from their founding to a customer ready prototype in 2 years. And they’re only just beginning. This instrument is just the first step towards a platform technology that will serve as the interface between the biological and digital world – as they continue to expand what is possible for their customers. Their desire for accessibility and openness is present in their company’s culture of communication and integrity, in the usability of their products, in their open exchange of ideas with their collaborators and in their commitment to their users complete ownership of their own data. They believe that in working this way, they have the opportunity to create not just a company, but a community that fundamentally improves how they live.
CMR Surgical develops a surgical robotic system for minimal access surgery. It makes minimal-access surgery universally accessible and affordable by significantly expanding the range of procedures that robots can perform and allowing surgeons to access 3D high-definition imagery and feedback during the operation.
Targeting pathways that modify RNA to deliver novel cancer therapeutics.
Origami is on a mission to build a green energy world, powered by smart technology. As renewables grow, energy markets are becoming more complex and volatile. Origami's intelligent trading and automation software enables energy companies to continuously harness the shifting commercial opportunities of the global energy transition and optimise increasingly complex physical, financial, and contractual positions. Origami's real-time data platform provides a modular suite of solutions incorporating state-of-the-art machine learning technology, all designed to deliver more efficient, resilient, and profitable trading operations across the entire power production, planning and energy trading workflow.
At Audio Analytic, we create exceptional human experiences through a greater sense of hearing. We do this by partnering with leading consumer tech companies to bring intelligence and context to their products through an accurate, robust and compact sense of hearing. This ‘greater sense of hearing’ will help us remember the past, help, improve and extend our hearing in the present and anticipate what we need in the very near future. Our embedded software platforms (ai3™ and ai3-nano™) have been licensed to some of the world’s most prominent companies and are suitable for a wide range of products from smart speakers and video doorbells to smartphones, xR glasses and true wireless earbuds.
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated.
MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins as a novel therapy for the treatment for pulmonary arterial hypertension Pulmonary arterial hypertension is a severe and life-limiting disease that affects the blood vessels in the lungs, leading to heart failure, and leaves sufferers feeling breathless and exhausted. Current treatments mainly target symptoms and the prognosis remains poor. The only effective cure is transplantation of the lungs or heart and lungs, which has associated risks and complications. Compromised bone morphogenetic protein (BMP) receptor type II (BMPR-II) signalling in endothelial cells plays a pivotal role in the pathobiology PAH, as identified from human genetic studies. BMP9 and 10 represent circulating ligands that selectively bind and activate BMPR-II receptor complexes on endothelial cells. Administration of exogenous BMP9 has been shown to augment endothelial BMPR-II signalling and reverse PAH in several rodent models of disease. Our goal is to explore the potential of BMP9 and BMP10 as potential therapies for PAH. The company follows the semi-virtual model with a hub based in Cambridge, UK. The company founders are experts in the field of PAH and BMPs. The team is staffed with experienced drug discovery professionals to direct an out-sourced development program. This model ensures maximum capital efficiency without sacrificing quality.
Jukedeck is developing an artificially intelligent music composer - a system that writes original music completely on its own. Jukedeck is based on state-of-the-art technology they are building that brings artificial intelligence to music composition and production. They are training deep neural networks to understand music composition at a granular level, so that they can build tools to aid creativity.
GeoSpock enables data fusion for the connected world with GeoSpock DB – the space-time analytics database. GeoSpock DB is a unique, cloud-native database optimised for querying for real-world use cases, able to fuse multiple sources of Internet of Things (IoT) data together to unlock its full value, whilst simultaneously reducing complexity and cost. GeoSpock DB enables efficient storage, data fusion, and rapid programmatic access to data, and allows you to run ANSI SQL queries and connect to standard analytics tools via flexible JDBC/ODBC connectors. Users are able to perform deep analysis and share insights using familiar toolsets, with plug and play support for common BI tools (such as Tableau™, Amazon QuickSight™, and Microsoft Power BI™), and Data Science and Machine Learning environments (including Python Notebooks and Apache Spark). The database can also be integrated with proprietary applications, web services, and internal tools – with compatibility for open-source and customisable visualisation libraries such as Kepler and Cesium.js.
Targeting pathways that modify RNA to deliver novel cancer therapeutics.
Imagen is a modular enterprise video platform that enables content owners to publish and monetize small and large-scale media archives. It helps companies of all sizes and industries to manage, search and distribute their media libraries securely.
Abcodia is a biotechnology company that focused on the discovery and validation of biomarkers for cancer screening. With its unique longitudinal serum biobank and partnerships with UCL, technology platform providers, and leading commercial diagnostic companies, Abcodia is able to support the end-to-end diagnostic development process. Abcodia was founded in 2010 and is based in Cambridge, UK.
Undo is the time travel debugging company for Linux. We equip developers with the technology to understand complex code and fix bugs faster. Developers spend far too much time figuring out what code actually does – either to find and fix bugs or to understand other people’s code. With time travel debugging, developers can see exactly what the software did, and create better software faster. By integrating Undo’s LiveRecorder into their CI workflow, C/C++, Go, and Java software teams can easily and quickly diagnose the root causes of new regressions, legacy bugs, and flaky tests – before they hit customers. Thousands of developers across leading technology firms including SAP, Juniper Networks, and Siemens use LiveRecorder to improve developer productivity, developer velocity, and software quality.
Congenica is a biotechnology company that provides a diagnostic decision support platform. They have translated this research into the gold standard clinical genomic analytics platform, Sapientia, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians to provide an actionable interpretation of genetic disease for patients. It was founded in 2013 and headquartered in Cambridge, Cambridgeshire.
Pragmatic is a ultra-low-cost flexible electronics. Their flexible integrated circuits (FlexICs) are thinner than human hair and can be invisibly embedded in objects, enabling innovators to create novel solutions to everyday problems that are not practical with conventional electronics. Designers can create their own application-specific flexible devices using our FlexIC Foundry® service at a fraction of the cost and time required for traditional silicon circuits, opening up multiple new markets. We also offer standard FlexIC products that extend proven applications such as RFID and NFC into mass market use cases, enabling the potential for trillions of smart objects that can engage with consumers and their environments. All FlexICs are manufactured on our revolutionary FlexLogIC® production system, a highly scalable manufacturing model for cost-effective high-volume production, achieved with orders of magnitude lower capital investment and operating cost compared to a traditional silicon IC fab. Our novel, differentiated technology is being adopted by a growing base of global companies across diverse markets, including consumer goods, retail, healthcare, pharmaceutical, gaming and security. Pragmatic is headquartered in Cambridge, UK, with our first billion-unit production facility in Sedgefield. Shareholders include Cambridge Innovation Capital, Arm and Avery Dennison.
Congenica is a biotechnology company that provides a diagnostic decision support platform. They have translated this research into the gold standard clinical genomic analytics platform, Sapientia, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians to provide an actionable interpretation of genetic disease for patients. It was founded in 2013 and headquartered in Cambridge, Cambridgeshire.
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated.
Origami is on a mission to build a green energy world, powered by smart technology. As renewables grow, energy markets are becoming more complex and volatile. Origami's intelligent trading and automation software enables energy companies to continuously harness the shifting commercial opportunities of the global energy transition and optimise increasingly complex physical, financial, and contractual positions. Origami's real-time data platform provides a modular suite of solutions incorporating state-of-the-art machine learning technology, all designed to deliver more efficient, resilient, and profitable trading operations across the entire power production, planning and energy trading workflow.
Jukedeck is developing an artificially intelligent music composer - a system that writes original music completely on its own. Jukedeck is based on state-of-the-art technology they are building that brings artificial intelligence to music composition and production. They are training deep neural networks to understand music composition at a granular level, so that they can build tools to aid creativity.
Imagen is a modular enterprise video platform that enables content owners to publish and monetize small and large-scale media archives. It helps companies of all sizes and industries to manage, search and distribute their media libraries securely.